Science

CRISPR makes prostate cancer vulnerable to immunotherapy

CRISPR makes prostate cancer vulnerable to immunotherapy illustration

The experimental treatment dramatically improved the effects of immunotherapy in mice and may offer hope for other hard-to-treat tumors. Comparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world data.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.

Leave a comment